Form 4: Galectin Therapeutics CFO Exercises and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Galectin Therapeutics' Chief Financial Officer, Jack W. Callicutt, exercised restricted stock units and sold the resulting shares under a pre-arranged 10b5-1 trading plan.
Summary
- Jack W. Callicutt, the Chief Financial Officer of Galectin Therapeutics, engaged in transactions involving the company's stock on December 23, 2024.
- He acquired 40,000 shares of common stock through the vesting of restricted stock units at no additional cost.
- Concurrently, he sold 40,000 shares of common stock at an average price of $0.8873 per share, with individual transactions ranging from $0.85 to $0.92.
- These transactions were executed under a previously disclosed 10b5-1 trading plan.
- Following these transactions, Mr. Callicutt directly owns 7,614 shares of Galectin Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document reflects routine insider trading activity under a pre-arranged plan, which is neither positive nor negative for the company's overall outlook.
Industry Context
This is a routine filing related to insider trading activity and is common for executives who receive stock-based compensation. The use of a 10b5-1 plan indicates a pre-planned strategy for selling shares.
Comparison to Industry Standards
- The use of 10b5-1 trading plans is a common practice among corporate executives to avoid accusations of insider trading.
- The reported transactions are typical for executives who receive stock options or restricted stock units as part of their compensation.
- Similar filings are regularly made by executives at comparable biotech companies such as Madrigal Pharmaceuticals (MDGL) and Viking Therapeutics (VKTX).
Stakeholder Impact
- The transactions have a minimal impact on shareholders as they are part of a pre-planned trading strategy and do not indicate a change in the company's fundamentals.
Key Dates
| Date | Description |
|---|---|
| 12/23/2024 | Date of the stock transactions, including the vesting of restricted stock units and the sale of common stock. |
| 12/26/2024 | Date of signature on the Form 4 filing. |
Keywords
Galectin Therapeutics, insider trading, Form 4, stock sale, restricted stock units, 10b5-1 plan, GALT, CFO, Jack W. Callicutt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.